• CTLT
• NVO

Consumer groups ask FTC to block Novo Holdings-Catalent deal

Consumer groups and unions oppose Novo Holdings' acquisition of Catalent, fearing reduced competition in weight loss and gene therapies, prompting a request for FTC review.

• CTLT
• LLY
• NVO

US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal

Senator Elizabeth Warren urges antitrust review of Novo Nordisk's $16.5 billion acquisition of Catalent, citing concerns over potential anti-competitive advantages in the obesity drug market.

• AZN
• LLY
• MBX
• NVO

MBX Biosciences earns Buy rating at three investment firms

Three investment firms have given MBX Biosciences a Buy rating, citing promising treatments and potential catalysts that could significantly boost the company's stock value.

• NVO

Novo Nordisk to invest $158 million in insulin plant in Brazil

Novo Nordisk will invest 864 million reais to upgrade a Brazilian factory pivotal to its insulin production, coinciding with a meeting between Brazilian and Danish leaders.

• CI
• CVS
• LLY
• NVO
• SNY
• UNH

Texas attorney general sues insulin makers and pharmacy middlemen over high costs

Texas AG Ken Paxton has sued insulin manufacturers and PBMs for inflating insulin prices, alleging collusion to benefit from high costs, challenging prior FTC actions targeting only PBMs.

• HIMS
• LLY
• NVO

Hims & Hers shares dip 9% after FDA says Lilly's weight-loss drug not in shortage

• LLY
• NOVOb
• NVO

Novo Nordisk stock valuation ‘very compelling’ says Bank of America

Bank of America lowers Novo Nordisk's price target amid cautious expectations for Wegovy and Ozempic, while maintaining a Buy rating due to upcoming CagriSema trial data potential.

• NVO

Novo Nordisk has mitigation plans to minimize disruption from port strikes

Novo Nordisk implements air freight plans to ensure production continuity amidst U.S. port strikes, which have minimal expected impact on essential goods availability, per HHS analysis.

• EVTG
• NVO

Evotec shares surge after technology partnership with Novo Nordisk

Evotec's shares increased 6% after a partnership with Novo Nordisk for cell therapy development, involving funding, R&D support, and exclusive rights for Novo Nordisk.

• MRK
• NVO

Challenge to US drug price negotiation program revived by appeals court

A U.S. appeals court has revived a lawsuit by healthcare groups challenging the Inflation Reduction Act's drug pricing negotiation provisions, asserting jurisdiction over claims against the Medicare negotiation program.